Clinical Trials Logo

Clinical Trial Summary

Caregivers of a person living with dementia (PLWD) experience high levels of prolonged stress that can lead to chronic problems with health, including increased risk of cardiovascular disease that is linked to autonomic dysregulation. Heart rate variability (HRV), measures of autonomic cardiovascular regulation, is decreased (worse) in caregivers of a person living with dementia. Autonomic function is linked to lateralization in the brain, and emerging neuromodulation methods that target lateralized signals in the brain, like Cereset (CR), may be able to improve heart rate variability. Therefore, this pilot study aims to test whether CR can improve HRV in caregivers of a person living with dementia experiencing stress, anxiety, or insomnia, as well as improve self-report measures of stress, sleep and caregiver burden.


Clinical Trial Description

The primary aims of this pilot study of 20 dementia caregivers experiencing symptoms of stress, anxiety or insomnia is to: 1) Evaluate the effect of Cereset (CR) to improve autonomic cardiovascular regulation measured as heart rate variability (HRV) and baroreflex sensitivity (BRS). Impact will be assessed based on changes in standard measures of HRV and BRS such as standard deviation of normal to normal R-R intervals (SDNN), the root mean square of successive differences between normal heartbeats (RMSSD), HF Alpha, and Sequence ALL. This will also provide blood pressure values evaluated by an automated oscillometric blood pressure device 2) Assess the effect of Cereset (CR) on self-reported symptom inventories of stress, anxiety, insomnia, and caregiver burden and distress 1. Insomnia as assessed by the Insomnia Severity Index (ISI) 2. Behavioral outcomes such as depression (as assessed by the Center for Epidemiological Studies-Depression Scale, (CES-D), anxiety (as evaluated by the generalized anxiety disorder (GAD-7), traumatic stress (as assessed by the Post-Traumatic Stress Disorder Checklist for Civilians (PCL-C), and stress (as assessed by the Perceived Stress Scale, (PSS) 3. Overall quality of life as evaluated using the measuring quality of life (QOLS) measure 4. Caregiver burden and distress measured with the Zarit Caregiver Burden scale and the Neuropsychiatric Inventory Questionnaire (NPI-Q) 5. Brief (4-item) caregiver self-efficacy scale ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05209438
Study type Interventional
Source Wake Forest University Health Sciences
Contact Dawn Higgins
Phone 336-716-9447
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 2022
Completion date April 2024

See also
  Status Clinical Trial Phase
Completed NCT03552159 - Behavioral Activation for Dementia Caregivers N/A